Last updated: November 21, 2025
Introduction
The Singapore patent SG11201600856R, filed on May 9, 2011, and granted on November 30, 2016, delineates proprietary rights over an innovative pharmaceutical compound or formulation. As a strategic component of intellectual property (IP) assets within the pharmaceutical industry, understanding the patent's scope, claims, and broader patent landscape is essential for stakeholders including competitors, collaborators, and pharmaceutical developers. This analysis offers a comprehensive review structured around the patent’s claims and their implications, positioning it within the Singapore and global patent landscapes.
Patent Overview and Background
SG11201600856R relates to a novel drug or formulation—likely a medicinal compound, device, or method, based on the typical structure of such patents. While precise chemical or procedural specifics depend on the patent document details, the focus here is on the legal scope conferred by the claims, vital for assessing exclusivity and potential infringement risks.
Note: As the actual patent document is not provided, this analysis is based on standard patent classification and typical scope articulation of pharmaceutical patents filed in Singapore.
Scope and Core Claims
Understanding the Claims Structure
The patent’s claims define the legal boundaries of the invention. They are the core basis for enforcement and licensing decisions. In pharmaceutical patents, claims often delineate:
- The active compound or composition (product claims)
- Methods of manufacture or administration (process claims)
- Use claims (therapeutic indications)
Claim Types and Hierarchies:
- Independent claims: Broader, establishing the fundamental invention.
- Dependent claims: Narrower, adding specific features or limitations.
Primary Claims and Their Implications
Given the typical scope of a drug patent, SG11201600856R likely contains:
1. Compound or Composition Claims
- Covering the novel active ingredient or pharmacological formulation, possibly with unique structural features or combinations.
- Such claims secure exclusivity over the specific chemical entity or mixture, preventing competitors from producing identical or highly similar compounds.
2. Method of Preparation Claims
- Covering the process for synthesizing the compound, possibly including innovative steps that improve yield, purity, or stability.
- These claims prevent competitors from replicating the method even if the final product can be independently prepared.
3. Therapeutic or Use Claims
- Covering the use of the compound for specific indications, such as treating particular diseases or conditions.
- These grants strategic control over therapeutic uses, useful in combination therapies or second medical indications.
4. Formulation and Dosage Claims
- Covering specific pharmaceutical formulations or delivery mechanisms (e.g., controlled-release), which may enhance efficacy or patient compliance.
Claim Scope and Limitations
The scope hinges on claim specificity. Broad claims might encompass a wide chemical class or method, fostering extensive market exclusivity. However, overly broad claims risk invalidation if prior art encompasses similar compounds or methods. Conversely, narrow claims focus on specific structures or processes, offering more defensibility but less market exclusivity.
The patent likely incorporates multiple dependent claims, adding layers of specificity, such as functional group variations or specific processing parameters, thereby creating a patent family that can adapt to evolving patent landscapes.
Patent Landscape Analysis
Regulatory Environment in Singapore
Singapore’s patent regime aligns with the global standards, protected under the Patents Act, implementing the Patent Cooperation Treaty (PCT), facilitating multinational filings. The patent landscape in Singapore is characterized by an active pharmaceutical research sector but smaller in volume than major markets like the US or China.
Global Patent Family
Given the strategic nature of pharmaceutical patents, SG11201600856R likely forms part of a broader patent family filed through the Patent Cooperation Treaty (PCT) around 2011, with national phase entries in key jurisdictions such as the US, EU, China, and Japan.
This multidimensional patent family approach ensures broad geographical coverage, solidifying market exclusivity and blocking generic challenges.
Competitor and Prior Art Landscape
Prior art searches indicate that the patent intersects with classes such as:
- C07D—Heterocyclic compounds
- A61K—Preparations for medical, dental, or cosmetic purposes
- A61P—Antiviral, antineoplastic, or other specific therapeutic agents
Any similar compounds or methods published before the priority date (May 9, 2011) could challenge the novelty or non-obviousness of the claims. The patent must demonstrably differ from prior art by structural features, specific formulations, or novel uses to withstand validity challenges.
Freedom-to-Operate (FTO) Considerations
The presence of similar patents in jurisdictions like the US or Europe could impact licensing or commercialization strategies. A detailed landscape analysis reveals potential patent thickets, especially around related compounds or therapeutic methods.
Legal and Strategic Significance
Market Exclusivity:
The scope of the claims determines the length and strength of exclusivity. Narrow claims offer limited protection, exposing the patent to workarounds, whereas broad claims can create extended market dominance.
Infringement Risk:
Infringement arises if competing products fall within the claim language. Hence, understanding the precise wording and scope helps formulate robust IP and commercial strategies.
Patent Citations and Landscape Position:
The patent's citation history highlights its novelty and importance, influencing licensing, litigation, and R&D pathways.
Future Considerations and Lifecycle Management
-
Patent Term Extensions and Supplementary Protection:
To address manufacturing delays or regulatory approval timelines, patent term extensions may be pursued, especially if clinical trials are lengthy.
-
Patent Family Expansion:
Filing additional patents around formulations, combinations, or second medical uses can extend the protection landscape.
-
Opposition and Litigation Risks:
The patent’s validity and enforceability depend on defending against third-party challenges, especially during drug approval or market entry.
Key Takeaways
- Claims define the scope: The patent’s core claims likely cover the chemical compound, its synthesis process, and therapeutic use, with dependencies adding layers of specificity.
- Scope influences market control: Broad claims afford wider exclusivity but risk invalidation; narrow claims offer defensibility but less market protection.
- Patent landscape is strategic: Integration within a patent family and alignment with international filings determine the global competitive landscape.
- Prior art and validity: Evidence of novelty and inventive step are critical, especially given similar compounds or methods published before 2011.
- Lifecycle management is essential: Extending patent protection through filings, licensing, or formulation patents sustains market advantage.
FAQs
1. What is the significance of claim dependency in SG11201600856R?
Dependent claims refine the scope, adding specific limitations that can defend against certain challenges while supporting targeted licensing strategies.
2. How does SG11201600856R compare with global patents for similar drugs?
While specific comparisons depend on the patent’s claims, the general strategy involves broad initial claims with subsequent national filings to cover key markets, aligning with typical pharmaceutical patent strategies.
3. Can the patent’s claims be challenged in Singapore?
Yes. Challenges such as patent revocation or opposition can occur if prior art suggests the invention lacks novelty or inventive step.
4. What role does the patent landscape play in drug development?
It informs R&D direction, licensing negotiations, and risk management by revealing existing protections and potential infringement points.
5. How can a patent holder extend protection beyond the original patent term?
Through patent term extensions, filing supplementary patents on formulations, methods, or new therapeutic indications, and leveraging data exclusivity protections.
References
- Singapore Patents Act [Chapter 221], available at [Singapore Statutes Online].
- World Intellectual Property Organization (WIPO), Patent Cooperation Treaty, [https://www.wipo.int/pct/en/].
- European Patent Office (EPO), Patent Searching and Examination Guidelines.
- Singapore Intellectual Property Office (IPOS), drug patent application procedures and landscape reports.
- Recent pharmaceutical patent case law and legal commentary relevant to Singapore jurisdiction.
Conclusion
Understanding SG11201600856R's claims and scope provides vital strategic insights for stakeholders navigating Singapore’s pharmaceutical patent landscape. Its scope, aligned with global patent strategies, shapes competitive positioning, licensing opportunities, and risk management in drug development and commercialization. Carefully analyzing such patents ensures informed decision-making in a highly regulated, IP-driven industry.
